Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

FDA approves 2 oncology drugs

by Shi En Kim
February 3, 2023 | A version of this story appeared in Volume 101, Issue 5

 

Two small-molecule anticancer drugs have been approved by the US Food and Drug Administration. One of them is Eli Lilly and Company’s pirtobrutinib, a reversible kinase inhibitor intended for adults who have mantle cell lymphoma and have completed at least two lines of systemic therapy. The Menarini Group’s estrogen receptor agonist elacestrant is another oncology drug to receive a nod, for the treatment of ER+, HER2–, or ESR1-mutated breast cancer in postmenopausal women and adult men. The Italian company is currently awaiting approval for the compound from the European Medicines Agency.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.